SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: KHS who wrote (20598)4/16/1999 12:13:00 AM
From: VLAD  Read Replies (2) of 23519
 
KHS,

My guess on Q1 product sales goes something like this:

1)Domestic sales about $3.5M
2)International sales about 1/2 of Q4 1998--my guess is about $3.5M
3)Milestone payments of $4M accounts for 12.5 cents profits.

In other words the CFO has done an EXCELLENT job controlling expenses because without the milestones, Vivus managed to break even. No marketing arm in the US market and a delayed European launch means a lot of room for some serious earnings improvements looking forward.

With AstraZeneca's European launch of MUSE next month along with a probable domestic partner in the near future, Vivus can see some SERIOUS earnings looking forward. IMHO based on forward looking earnings potential Vivus is CHEAP even at $10.00/share.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News